Tetralogic Pharmaceuticals Corp Stock Short Ratio
| TLOGDelisted Stock | USD 0.0001 0.00 0.00% |
TetraLogic Pharmaceuticals Corp fundamentals help investors to digest information that contributes to TetraLogic Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of TetraLogic Pink Sheet. The fundamental analysis module provides a way to measure TetraLogic Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TetraLogic Pharmaceuticals pink sheet.
TetraLogic |
TetraLogic Pharmaceuticals Corp Company Short Ratio Analysis
TetraLogic Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current TetraLogic Pharmaceuticals Short Ratio | 4.39 X |
Most of TetraLogic Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TetraLogic Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, TetraLogic Pharmaceuticals Corp has a Short Ratio of 4.39 times. This is 12.56% higher than that of the Biotechnology sector and 40.76% lower than that of the Health Care industry. The short ratio for all United States stocks is 9.75% lower than that of the firm.
TetraLogic Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TetraLogic Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of TetraLogic Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TetraLogic Pharmaceuticals by comparing valuation metrics of similar companies.TetraLogic Pharmaceuticals is currently under evaluation in short ratio category among its peers.
TetraLogic Fundamentals
| Return On Asset | -0.2 | ||||
| Current Valuation | 458.72 K | ||||
| Shares Outstanding | 24.47 M | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 1.18 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (43.15 M) | ||||
| Net Income | (49.72 M) | ||||
| Cash And Equivalents | 5.89 M | ||||
| Cash Per Share | 0.24 X | ||||
| Total Debt | 28.33 M | ||||
| Debt To Equity | 4.17 % | ||||
| Current Ratio | 0.48 X | ||||
| Book Value Per Share | (1.25) X | ||||
| Cash Flow From Operations | (34.89 M) | ||||
| Short Ratio | 4.39 X | ||||
| Earnings Per Share | (1.65) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 29 | ||||
| Beta | 3.0 | ||||
| Market Capitalization | 229.36 K | ||||
| Total Asset | 64.02 M | ||||
| Retained Earnings | (175.56 M) | ||||
| Working Capital | 18.31 M | ||||
| Current Asset | 21.97 M | ||||
| Current Liabilities | 3.66 M | ||||
| Z Score | -2.8 | ||||
| Net Asset | 64.02 M |
About TetraLogic Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TetraLogic Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TetraLogic Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TetraLogic Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in TetraLogic Pink Sheet
If you are still planning to invest in TetraLogic Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TetraLogic Pharmaceuticals' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |